Chronic lymphocytic leukemia medical therapy
|
Chronic lymphocytic leukemia Microchapters |
|
Differentiating Chronic lymphocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic lymphocytic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Chronic lymphocytic leukemia medical therapy |
|
Directions to Hospitals Treating Chronic lymphocytic leukemia |
|
Risk calculators and risk factors for Chronic lymphocytic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
The mainstay of therapy for symptomatic chronic lymphocytic leukemia patients is immunochemotherapy.[1] Asymptomatic chronic lymphocytic leukemia patients are managed with observation and follow-up, whereas symptomatic chronic lymphocytic leukemia patients are treated with immunochemotherapy. Immunochemotherapies used for the treatment of chronic lymphocytic leukemia patients include purine analogues, alkylating agents, monoclonal antibodies, corticosteroids, tyrosine kinase inhibitors, and B-cell receptor pathway inhibitors.[1][2] Radiation therapy is not recommended for the management of chronic lymphocytic leukemia patients.[3][4][5]
Immunochemotherapy
- The mainstay of therapy for symptomatic chronic lymphocytic leukemia patients is immunochemotherapy.[1][4][5]
- Asymptomatic chronic lymphocytic leukemia patients are managed with observation and follow-up, whereas symptomatic chronic lymphocytic leukemia patients are treated with immunochemotherapy.
- Indications to initiate immunochemotherapy among patients with chronic lymphocytic leukemia include:[3]
- Symptomatic chronic lymphocytic leukemia patients presenting with:
- Fever of unknown origin (>38.1°C for a period greater than two weeks)
- Night sweats for more than one month
- Unintentional significant weight loss over a period of six months
- Patients presenting with thrombocytopenia or anemia due to bone marrow failure
- Patients presenting with refractory autoimmune hemolytic anemia or refractory autoimmune thrombocytopenia
- Evidence of symptomatic splenomegaly, with the spleen being palpated more than 6cm below the costal margin
- Evidence of symptomatic progressive lymph nodes swelling, with a size greater than 10 cm in diameter
- Evidence of a rapidly progressive lymphocytosis, which might be observed as:
- An increase of greater than 50% over a 2-month period
- A lymphocyte doubling period shorter than six months
- Immunochemotherapies used for the treatment of chronic lymphocytic leukemia patients include purine analogues, alkylating agents, monoclonal antibodies, corticosteroids, tyrosine kinase inhibitors, and B-cell receptor pathway inhibitors.[1][2]
- Purine analogues used for the management of chronic lymphocytic leukemia patines may include:
- Alkylating agents used for the management of chronic lymphocytic leukemia patients may include:
- Monoclonal antibodies used for the management of chronic lymphocytic leukemia patients may include:
- Immunomodulatory agents used for the management of chronic lymphocytic leukemia patients may include:
- Corticosteroids used for the management of chronic lymphocytic leukemia patients may include:
- Tyrosine kinase and B-Cell receptor pathway inhibitors used for the management of chronic lymphocytic leukemia patients may include:
- Idelalisib (targets phosphoinositide 3-kinase delta)
- Ibrutinib (targets bruton tyrosine kinase)
- The optimal immunochemotherapeutic regimens used for the management of chronic lymphocytic leukemia depends on a number of factors which include:[3][4][5]
- The clinical presentation of the patients
- The performance status of the patients
- The stage of the tumor
- The presence of specific genetic mutations
- First line therapy vs. refractory/relapsed therapy
- The algorithm below summarizes the management approach for chronic lymphocytic leukemia patients:[1][2][3]
Initial patients evaluation | |||||||||||||||||||||||||||||||||||||||||||||
History Physical examination Complete blood count | |||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||
Rai Staging System Binet Staging System | |||||||||||||||||||||||||||||||||||||||||||||
Rai stage 3-4 Binet stage B-C | Rai stage 0-2 Binet stage A | ||||||||||||||||||||||||||||||||||||||||||||
Evaluate patients by cumulative index illness rating scale | Patients managed by observation and close follow-up | ||||||||||||||||||||||||||||||||||||||||||||
Frail patients (CIRS ≥6) | Fit patients (CIRS <6) | ||||||||||||||||||||||||||||||||||||||||||||
FISH chromosomal analysis | |||||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion can be found here | Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion can be found here | Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion can be found here | |||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic Regimens for The Management of Patients Without Chromosome 17p Deletion or Chromosome 11q Deletion
First Line Therapy
- Preferred immunochemotheraptic regimens for the treatment of such patients who are older than 70 years of age (or younger than 70 years of age with a poor performance status) include (in order of preference):[2]
- Obinutuzumab AND chlorambucil
- Ofatumumab AND chlorambucil
- Rituximab AND chlorambucil
- Bendamustine ± rituximab
- Obinutuzumab
- Fludarabine ± rituximab
- Chlorambucil
- Rituximab
- Cladribine
- Preferred immunochemotheraptic regimens for the treatment of such patients who are younger than 70 years of age with a good performance status include (in order of preference):
- Fludarabine AND cyclophosphamide AND rituximab
- Fludarabine AND rituximab
- Pentostatin AND cyclophosphamide AND rituximab
- Bendamustine AND rituximab
Refractory/Relapsed Therapy
- Preferred immunochemotheraptic regimens for the treatment of such patients who are older than 70 years of age (or younger than 70 years of age with a poor performance status) include (in order of preference):[2]
- Ibrutinib
- Idelalisib ± rituximab
- Fludarabine AND cyclophosphamide AND rituximab (reduced dose)
- Pentostatin AND cyclophosphamide AND rituximab (reduced dose)
- Bendamustine ± rituximab
- High-dose methylprednisolone AND rituximab
- Ofatumumab
- Obinutuzumab
- Lenalidomide ± rituximab
- Alemtuzumab ± rituximab
- Dose-dense rituximab
- Preferred immunochemotheraptic regimens for the treatment of such patients who are younger than 70 years of age with a good performance status include (in order of preference):
- Ibrutinib
- Idelalisib ± rituximab
- Fludarabine AND cyclophosphamide AND rituximab
- Pentostatin AND cyclophosphamide AND rituximab
- Bendamustine ± rituximab
- Fludarabine AND alemtuzumab
- Rituximab AND cyclophosphamide AND doxorubicin AND vincristine AND cytarabine
- Oxaliplatin AND fludarabine AND cytarabine AND rituximab
- Ofatumumab
- Obinutuzumab
- Lenalidomide ± rituximab
- Alemtuzumab ± rituximab
- High-dose methylprednisolone AND rituximab
Immunochemotherapeutic Regimens for The Management of Patients With Chromosome 17p Deletion
First Line Therapy
- Preferred immunochemotheraptic regimens for the treatment of such patients regardless the age group include (in order of preference):[2]
- Ibrutinib
- High-dose methylprednisolone AND rituximab
- Fludarabine AND rituximab
- Fludarabine AND cyclophosphamide AND rituximab
- Obinutuzumab AND chlorambucil
- Alemtuzumab ± rituximab
- Rituximab AND chlorambucil
Refractory/Relapsed Therapy
- Preferred immunochemotheraptic regimens for the treatment of such patients regardless the age group include (in order of preference):
- Ibrutinib
- Idelalisib ± rituximab
- High-dose methylprednisolone AND rituximab
- Lenalidomide ± rituximab
- Ofatumumab
- Oxaliplatin AND fludarabine AND cytarabine AND rituximab
Immunochemotherapeutic Regimens for The Management of Patients With Chromosome 11q Deletion
First Line Therapy
- Preferred immunochemotheraptic regimens for the treatment of such patients who are older than 70 years of age (or younger than 70 years of age with a poor performance status) include (in order of preference):[2]
- Obinutuzumab AND chlorambucil
- Ofatumumab AND chlorambucil
- Rituximab AND chlorambucil
- Bendamustine ± rituximab
- Cyclophosphamide AND prednisone ± rituximab
- Fludarabine AND cyclophosphamide AND rituximab (reduced dose)
- Rituximab
- Preferred immunochemotheraptic regimens for the treatment of such patients who are younger than 70 years of age with a good performance status include (in order of preference):
- Fludarabine AND cyclophosphamide AND rituximab
- Bendamustine ± rituximab
- Pentostatin AND cyclophosphamide AND rituximab
- Obinutuzumab AND chlorambucil
Supportive Therapy
Infections Prophylaxis
- Pneumococcal vaccine administered every five years
- Influenza vaccine administered annually
- Live attenuated vaccines should be avoided among chronic lymphocytic leukemia patients.
- Other strategies for the prevention of opportunistic infections include:
- Sulfamethoxazole/trimethoprim can be administered to patients receiving purine analogues as a prophylaxis for pneumocystis pneumonia infection
- Acyclovir can be administered to patients receiving purine analogues as a prophylaxis for herpes simplex virus infection.
Autoimmune Cytopenia Prophylaxis
- Corticosteroids is recommended for the management of autoimmune cytopenia among chronic lymphocytic leukemia patients. Other therapeutic measures may include:[2]
- Romiplostim is recommended for the management of autoimmune thrombocytopenia among chronic lymphocytic leukemia patients.
Thromboprophylaxis
- A daily aspirin dose is recommended among chronic lymphocytic leukemia patients who receive lenalidomide while their platelet count is greater than 50×10¹²/L.[2]
Radiation Therapy
- Radiation therapy is not recommended for the management of chronic lymphocytic leukemia patients.[1][2][3][4][5]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Nabhan C, Rosen ST (2014). "Chronic lymphocytic leukemia: a clinical review". JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 NCCN Guidelines Version 2.2015 CLL/SLL. National Comprehensive Cancer Network. (2015) http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf Accessed on October, 15 2015
- ↑ 3.0 3.1 3.2 3.3 3.4 Hallek M (2015). "Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment". Am J Hematol. 90 (5): 446–60. doi:10.1002/ajh.23979. PMID 25908509.
- ↑ 4.0 4.1 4.2 4.3 Chronic Lymphocytic Leukemia. Wikipedia (2015) https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Complications Accessed on October, 17 2015
- ↑ 5.0 5.1 5.2 5.3 Chronic Lymphocytic Leukemia Treatment –for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq Accessed on October, 17 2015